Kowa Pharmaceuticals America Announces Strategic Divestiture of Diclofenac Assets

Kowa has announced plans to divest its unique franchise of diclofenac products

14.04.2009

Kowa Pharmaceuticals America Announces Strategic Divestiture

Montgomery, AL, April 14, 2009 - Kowa Pharmaceuticals America, Inc., (KPA) a privately-held specialty pharmaceutical company headquartered in Montgomery, AL, has announced plans to divest its unique franchise of diclofenac products, including PRO-513 (proposed trade name: CAMBIATM) for the treatment of acute migraine headache pain and PRO-571 for the treatment of acute pain. KPA has appointed Robert W. Baird & Co. as its exclusive financial advisor with regard to a transaction involving these assets.

Download Material

This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. Find out more.

X